• 제목/요약/키워드: Anti-hepatitis B virus

검색결과 102건 처리시간 0.025초

대구시내(大邱市內) 의과대학생(醫科大學生)들의 B형(型)바이러스성(性) 간염감염율(肝炎感染率) (Hepatitis B Virus Infection Rate of Medical School Students in Taegu)

  • 박정한;윤태현;천병렬;송정흡
    • Journal of Preventive Medicine and Public Health
    • /
    • 제20권1호
    • /
    • pp.129-136
    • /
    • 1987
  • 의대생들의 B형바이러스성 간염의 감염율을 조사하고 그 예방대책을 강구하기 위하여 경북의대 1, 2, 3학년 가운데 B형 간염 백신 예방접종을 받은 학생을 제외한 자원자 385명을 대상으로 HBsAg, anti-HBs, anti-HBc를 RIA방법으로 측정하여 B형간염 감염율을 조사하고 설문지로 수혈력, 침술력, 수술력을 조사하고 HBsAg양성인 사람은 16개월 후에 재검사하여 변화양상을 조사하였다. HBsAg양성율은 6.8%이었으며 연령에 대한 보정을 했을 때 남자가 7.2%로 여자의 4.9%보다 높았으며, anti-HBs양성율은 35.8% (남자 36.1%, 여자 37 9%), anti-HBc양성율은 45.5% (남자 46.5%, 여자 44.5%)이었다. 따라서 B형간염 감염율은 49.1%로서 역시 남자(50.3%)가 여자보다(46.5%) 높았다. 학년별 HBsAg양성율 및 HBV감염율의 차이는 연령구성의 차이에 기인된 것 이었으며 연령별 HBsAg양성율은 20세가 1.7%, 21세 6.6%, 22세 6.1%, 23세 12.2%, 24세 이상에서 6.4%로 23세에서 가장 높게 나타났다. HBV감염율은 20세에서 45.8%, 21세 41.5%, 22세 49.5%, 23세 55.4%, 24세이상에서 59.6%로 나타나 연령이 증가할수록 감염율은 증가하였다. 이와같은 연령별 차이는 통계적으로 유의한 것은 아니었으나 타 연구결과와 종합해 볼 때 연령별 차이가 있을 것으로 생각되므로 같은 연령의 다른 학교 및 다른 계층을 대상으로 조사해 보고 연령에 따른 차이가 생기는 이유를 규명한다면 이 연령층에서 B형간염의 주요전파 경로를 밝힐 수 있을 것으로 생각된다. HBsAg양성인 26명가운데 1명만이 B형간염을 않고 있는 환자로 밝혀졌고 이들은 16개월 후에 재경사한 결과 검사에 응한 24명 중 22명이 계속 HBsAg양성이고 2명은 음성으로 되고 anti-HBs가 양성으로 나타났다. 본 연구 결과로 보아 20세 이전에 약 반이 B형간염에 감염되었고 재학중에도 감염이 일어나고 있으므로 입학 즉시 감염여부를 확인하고 미감염자에 대해 예방접종을 실시하고 임상에 종사하기 시작할 때 추가접종하는 것이 이상적일 것으로 생각된다.

  • PDF

적혈구 농축제재에서 HBV DNA의 노출정도 (Prevalence of HBV DNA in Packed Red Blood Cells)

  • 이채훈;김정숙;송달효
    • Journal of Yeungnam Medical Science
    • /
    • 제12권2호
    • /
    • pp.339-346
    • /
    • 1995
  • 수혈 후 B형 간염 바이러스의 전파를 감소시키기 위한 방법으로 현재 적십자 혈액원에서 공급되는 적혈구 농축제재를 대상으로 HBV DNA, HBsAg, anti-HBs 및 anti-HBc를 측정 하여 수혈자에서 HBV DNA의 노출정도와 HBV DNA와 B형 바이러스 간염의 혈청학적 표지자와의 관련성을 조사하여 다음과 같은 결과를 얻었다. 대구 적십자 혈액원에서 공급되는 적혈구 농축제재에서는 HBsAg이 검출되지 않았으며, HBV DNA는 0.6%에서 검출되었는데, 모두 anti-HBc만 양성인 경우였다. Anti-HBc양성률은 37%였으며, 이들중 65.8%에서 anti-HBs도 양성으로 나타나 anti-HBc만 양성인 경우는 공혈혈액의 13.0% 정도로 추정되었다. 따라서, 우리나라와 같이 anti-HBc양성률이 높은 지역에서는 anti-HBs를 추가하는 경우 13%의 혈액제제만을 폐기함으로써 HBV DNA의 전파를 차단시킬수 있으리라 생각되며 현재 실시하고 있는 검사보다 예민도와 특이도가 높은 선별검사의 개발이 필요한 것으로 생각된다.

  • PDF

C형 간염바이러스(HCV)의 NS5B RNA Replicase에 의해 그 활성이 조절되는 HCV지놈 표적 Hammerhead 리보자임 개발 (Development of Hepatitis C Virus (HCV) Genome-Targeting Hammerhead Ribozyme Which Activity Can Be Allosterically Regulated by HCV NS5B RNA Replicase)

  • 이창호;이성욱
    • 미생물학회지
    • /
    • 제43권3호
    • /
    • pp.159-165
    • /
    • 2007
  • C형 간염바이러스(hepatitis C virus; HCV)증식을 효과적이며 특이적으로 제어할 수 있는 유전산물을 개발하기 위하여 HCV 중식조절이자인 NS5B RNA replicase 존재에 의해 allosteric하게 그 활성 이 조절될 수 있는 HCV internal ribosome entry site (IRES) 표적 hammerhead 리보자임을 개발하였다. 우선 HCV IRES 염기서열 중+382 nucleotide(nt) 부위가 리보자임에 의해 가장 잘 인식되었음을 관찰하였다. 이러한 allosteric 리보자임은 NS5B RNA replicase와 특이적으로 결합하는 RNA aptamer 부위, aptamer와 NS5B와의 결합에 의해 리보자임 활성을 유도할 수 있도록 구조적 변이를 전달할 수 있는 communication module부위 및 HCV IRES의 +382 nt를 인지하는 hammerhead 리보자임 등으로 구성되도록 설계하였다. 특히 in vitro selection기법을 활용하여 NS5B 의존적으로 리보자임 활성을 증가시킬 수 있는 communication module 염기서열을 밝혀내었다. 이러한 리보자임은 단백질이 없거나 대조 단백질인 bovine serum albumin이 존재할 때에는 절단반응을 유도하지 못하였으나 HCV NS5B 단백질이 존재할 매에만 효과적으로 NS5B 농도 의존적으로 절단 반응을 유도할 수 있음을 관찰하였다. 이러한 allosteric 리보자임은 HCV중식의 효과적인 증식 억제 선도물질 뿐만 아니라 HCV 치료선도물질의 스크리닝용 도구 및 HCV 조절 인자를 탐색할 수 있는 HCV 진단용 리간드로서도 활용될 수 있을 것이다.

Current Status of Anti-HBV Chemotherapy

  • Hong, Joon H.;Choi, Yong-Seok;Chun, Byoung K.;Lee, Kyeong;Chu, Chung K.
    • Archives of Pharmacal Research
    • /
    • 제21권2호
    • /
    • pp.89-105
    • /
    • 1998
  • In the past decade, significant progress has been achieved in the battle against hepatitis B virus. In addition to the immunomodulating agents such as interferon-.alpha., and thymosin, many novel antiviral agents have been discovered, among which nucleoside analogues are the mainstay. New-generation compounds such as 3TC and famciclovir have shown promise in the treatment of patients chronically infected by this virus, and are on the line for approval. However, viral rebound after cessation of therapy still remains a major problem. Additionally, the reports on the drug resistance to these antiviral agents suggest that combination therapy will be the eventual strategy (Bartholomew et al., 1997; Tipples et al., 1996). Therefore, developments of safe and effective antiviral agents which do not cross-resist with currently available antiviral drugs are still much needed.

  • PDF

B형 간염 전파관련요인에 관한 역학적 연구 (An Epidemiological Study on the Selected Risk Factors of Hepatitis B Virus Infection)

  • 오민화
    • Journal of Preventive Medicine and Public Health
    • /
    • 제17권1호
    • /
    • pp.223-229
    • /
    • 1984
  • An attempt to confirm the associations of some selected risk factors of HBV infection and measure their risks, a cross-sectional study with 1,209 urban office workers was carried out. For the study, a simple questionnaire which contained several questions on personal experience and behaviors on several known selected risk factors of HBV infection was applied to each subject, and the Hepatitis B virus surface antigen and its antibody were checked by RPHA and PHA method, respectively. Risk factors chosen for this study were experience of blood transfusion and personal contact variables, such as frequencies of eating-out, drinking after office hours, going to tea room, sharing cigarettes, etc. The results obtained were as follows: 1. The proportion of HBsAg positive was 10.6%, and total HVB infected including the Anti-HBs positive cases without vaccination was 44.2%. Both were higher in male than in female. 2. Frequent personal contact through glasses and dishes in eating-outs and drinkings turned out not to be a significant risk factor of Hepatitis B surface antigenecity. 3. Frequent visits to tea room was a significant risk factor of HBV infection which combined HBsAg positive cases and Anti-HBs cases who had not received HBV vaccination. The odds ratio was 1.56 4. Blood transfusion was not a significant risk factor of both HBsAg positive and total HBV infection. In summary, indirect oral contacts through eating-outs and drinkings was not significant risk factor in Korea at least between adults. Blood transfusion is no more major source of HBV infection in Korea probably because the adquate screening test of HBsAg for the blood donors is being made.

  • PDF

Synthesis and Antiviral Activity of 2'(β)-Hydroxymethylated Carbodine Analogues Against Hepatitis C Virus

  • Hong, Joon-Hee;Oh, Chang-Hyun
    • Bulletin of the Korean Chemical Society
    • /
    • 제30권11호
    • /
    • pp.2626-2630
    • /
    • 2009
  • 2'($\beta$)-Hydroxymethylated adenosine is a potent and selective inhibitor of hepatitis C virus (HCV) replication. It targets the RNA-dependent RNA polymerase of HCV, NS5B. Synthesis and antiviral evaluation of carbocyclic versions are described. The cyclopentene intermediate ($9\beta$) was successfully synthesized through sequential Johnson-Claisen orthoester rearrangement and ring-closing metathesis (RCM). Coupling of bases via a Pd(0) catalyst, selective dihydroxylation, and desilylation yielded the target nucleoside analogues. The compounds 17 and 18 were assayed for their ability to inhibit HCV RNA replication in a subgenomic replicon Huh7 cell line and showed moderate antiviral activity with toxicity up to 20.0 and 24.7 ${\mu}g/mL$, respectively.

Differential Expression of HCV Core Protein from Two Different Quasispecies

  • Yu, Kyung-Lee;You, Ji-Chang
    • Biomolecules & Therapeutics
    • /
    • 제17권2호
    • /
    • pp.151-155
    • /
    • 2009
  • Hepatitis C virus (HCV) has genetic diversity like most of RNA viruses. HCV major genotypes are classified into several subtypes which are further divided into quasispecies having, genetically different but closely related variants. The HCV core that is a nucleocapsid protein located at the amino terminus of the viral polyprotein is relatively a conserved protein among the HCV isolates and thus it has been one of plausible targets for anti-HCV drug development. However, different quasispecies of HCV core gene have also been found. In this study, we compared the expression level of core protein between two different quasispecies of HCV genotype 1b. Our data demonstrate that a little differences of amino acid sequence lead to substantial difference of expression level. It might be another important reason of different pathogenesis among HCV infected patients.

Hepatitis C Virus Prevalence and Genotyping among Hepatocellular Carcinoma Patients in Baghdad

  • Al-Kubaisy, Waqar Abd Al Qahar;Obaid, Kadhim Jawad;Noor, Nor Aini Mohd;Ibrahim, Nik Shamsidah Binti Nik;Al-Azawi, Ahmed Albu-Kareem
    • Asian Pacific Journal of Cancer Prevention
    • /
    • 제15권18호
    • /
    • pp.7725-7730
    • /
    • 2014
  • Hepatocellular carcinoma (HCC) is the third most common cause for cancer death in the world, now being especially linked to chronic hepatitis C virus (HCV) infection. This case-control study consisting of 65 HCC patients and 82 patients with other malignant tumours as controls was conducted to determine the association of HCV markers with HCC. Serum of each participant was obtained for detection of HCV Ab and RNA by DNA enzyme immunoassay (DEIA). Twenty six per cent (26.0%) of HCC patients had positive anti-HCV which was significantly greater than the control group (p=0.001). HCC patients significantly have a risk of exposure to HCV infection almost 3 times than the control group (OR=2.87, 95% C.I=1.1-7). Anti-HCV seropositive rate was significantly (p=0.03) higher among old age HCC patients and increases with age. Males with HCC significantly showed to have more than 9 times risk of exposure to HCV infection (OR=9.375, 95 % CI=1.299-67.647) than females. HCV-RNA seropositive rate was (70.8%) significantly higher among HCC patients compared to (22.2%) the control group (p=0.019). The most prevalent genotype (as a single or mixed pattern of infection) was HCV-1b. This study detected a significantly higher HCV seropositive rate of antibodies and RNA in HCC patients.

Epidemiology of Hepatitis C Virus Genotypes in Northeastern Thai Blood Samples

  • Barusrux, Sahapat;Sengthong, Chatchawan;Urwijitaroon, Yupa
    • Asian Pacific Journal of Cancer Prevention
    • /
    • 제15권20호
    • /
    • pp.8837-8842
    • /
    • 2014
  • Background: Hepatitis C virus (HCV) infection is an important cause of liver cancer in Thailand. The highest prevalence of anti-HCV positive among Thai blood donors is found in the northeastern region. The present analysis of the genotype distribution among anti-HCV positive northeastern-Thai blood donors was conducted to provide a base for the epidemiological pattern of HCV infection in this region. Materials and Methods: A total of 112 HCV seropositive healthy blood donors were randomly selected and tested for the presence of HCV-RNA by RT-PCR. HCV-RNA positive samples were genotyped by direct sequencing at core region genomes and confirmed by phylogenetic analysis. Results: HCV viremia was found in 94.6% (106/112) of HCV seropositive blood donors. There were 3 major genotypes distributed among this population. HCV genotype 3a was the most prevalent (71.7%) followed by genotypes 1a (7.5%), 1b (7.5%), 6i (3.8%), 6f (2.8%) and 6n (1.9%). Conclusions: HCV genotype 3a in asymptomatic infections in northeastern Thailand is significantly higher than other previous reports. Subgenotype 6 prevalence is less than in neighboring countries and distribution patterns differ. The findings are relevant as predictors for using interferon therapy in this population.

Elimination of Mother-to-Infant Transmission of Hepatitis B Virus: 35 Years of Experience

  • Lu, Fang-Ting;Ni, Yen-Hsuan
    • Pediatric Gastroenterology, Hepatology & Nutrition
    • /
    • 제23권4호
    • /
    • pp.311-318
    • /
    • 2020
  • Chronic hepatitis B viral (HBV) infection remains a major health threat, especially in high-prevalence areas. Most infants infected by mother-to-infant HBV transmission become chronic carriers. In Taiwan, many important preventive interventions have been implemented to block the perinatal transmission of HBV in the past 35 years. The first nationwide universal HBV vaccination program was launched in Taiwan in July 1984. The three-dose HBV vaccine completion rate reached 98.1% in 2018. The prevalence of Hepatitis B surface antigen (HBsAg) decreased from 9.8% in pre-vaccinated period in 1984 to 0.5% in the vaccinated cohort in 2014. The incidence of hepatocellular carcinoma in children aged 6-9 years significantly declined from 0.52 to 0.13 per 100,000 children born before and after 1984, respectively. Furthermore, we have performed a maternal HBV screening program during pregnancy since 1984, with the screening rate peaked at 93% in 2012. The HBsAg- and HBeAg-seropositive rate in pregnant women declined from 13.4% and 6.4% in 1984-1985 to 5.9% and 1.0% in 2016, respectively. To closely control perinatal HBV infection, we have administered hepatitis B immunoglobulin immediately after birth and checked the serum level of HBsAg and anti-HBs in high-risk babies born to HBsAg-seropositive mothers, irrespective of their HBeAg status, since July 2019. We have also adopted short-term antiviral treatments such as tenofovir 300 mg daily in the third trimester for highly viremic mothers and reduced the perinatal infection rates from 10.7 to 1.5%. Through all these efforts, we expect to meet the global goal of eliminating HBV infection by 2030.